1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Computer-Aided Drug Discovery Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Computer-Aided Drug Discovery Market Revenue and Volume, by Type
8.1.1 Structure-based Drug Design
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Ligand-based Drug Design
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Sequence-based Approaches
8.1.3.1. Market Revenue and Volume Forecast
9.1. Computer-Aided Drug Discovery Market Revenue and Volume, by Therapeutic Area
9.1.1. Oncology
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Neurology
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Cardiovascular diseases
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Respiratory diseases
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Diabetes
9.1.5.1. Market Revenue and Volume Forecast
10.1. Computer-Aided Drug Discovery Market Revenue and Volume, by March
10.1.1. Pharmaceuticals companies
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Biotechnology companies
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Research Laboratories
10.1.3.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type
11.1.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.1.3. Market Revenue and Volume Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type
11.1.4.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.1.4.3. Market Revenue and Volume Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type
11.1.5.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.1.5.3. Market Revenue and Volume Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type
11.2.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.2.3. Market Revenue and Volume Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type
11.2.4.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.2.4.3. Market Revenue and Volume Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type
11.2.5.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.2.5.3. Market Revenue and Volume Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type
11.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.2.6.3. Market Revenue and Volume Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type
11.2.7.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.2.7.3. Market Revenue and Volume Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type
11.3.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.3.3. Market Revenue and Volume Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type
11.3.4.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.3.4.3. Market Revenue and Volume Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type
11.3.5.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.3.5.3. Market Revenue and Volume Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type
11.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.3.6.3. Market Revenue and Volume Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type
11.3.7.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.3.7.3. Market Revenue and Volume Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type
11.4.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.4.3. Market Revenue and Volume Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type
11.4.4.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.4.4.3. Market Revenue and Volume Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type
11.4.5.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.4.5.3. Market Revenue and Volume Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type
11.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.4.6.3. Market Revenue and Volume Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type
11.4.7.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.4.7.3. Market Revenue and Volume Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type
11.5.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.5.3. Market Revenue and Volume Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type
11.5.4.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.5.4.3. Market Revenue and Volume Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type
11.5.5.2. Market Revenue and Volume Forecast, by Therapeutic Area
11.5.5.3. Market Revenue and Volume Forecast, by End User
12.1. Albany Molecular Research Inc. (AMRI)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BOCSCI Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AstraZeneca
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bioduro-Sundia
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Schrödinger, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bayer AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Aragen Life Sciences Pvt. Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Charles River Laboratories
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Aris Pharmaceuticals
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Albany Molecular Research Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
